Soap, Cleaning Compound, and Toilet Preparation Manufacturing (U.S.) — An Investor's Primer

NAICS 2022 code 3256. NAICS is the North American Industry Classification System, the U.S. federal standard for sorting businesses into industries. This is a four-digit "industry group" that rolls up two five-digit industries: 32561 (soap and cleaning compounds) and 32562 (toilet preparations — the government's label for beauty and personal care).

1. Overview

This industry group is the country's factory floor for consumer chemistry — the products people rub on their skin, wash with, spray, and clean their homes with. It bundles two businesses that share a chemistry and a shelf but sell very different promises: one cleans (laundry and dish detergent, bar and liquid soap, disinfectants, polishes, plus the bulk surfactant chemistry underneath them), and the other beautifies (perfume, makeup, skincare, sunscreen, shampoo, deodorant, shaving preparations, toothpaste).

In 2022 the two together shipped about $82.4 billion of product from U.S. plants, and in 2023 they employed roughly 106,000 people across about 2,500 factories — on the Census Bureau's employer-establishment count, which is not the only federal read on headcount (see §3).[1][2] What unites them is an economic model, not a molecule: in both, the physical product is cheap to make and most of the value lives in brand, formulation, and marketing — which is why both are unusually recession-resilient and both are dominated by a small club of giant, diversified consumer-goods companies.

But the reason to read a group-level page rather than jump straight to a child primer is the contrast between the two children. They differ in size, in how fast they grow, in how internally varied they are, and — most usefully for an investor — in where the listed pure-plays are. The cleaning side is bigger, flatter, internally three quite different businesses stacked in a supply chain, and has essentially no focused public consumer stock (you buy diversified staples). The beauty side is smaller, growthier, a single homogeneous industry, and it is where the tradable pure-plays cluster. This primer leads with that comparison, then covers the group as a whole.

2. What's inside — the two child industries and how they differ

The four-digit group splits into two five-digit industries. They are close cousins in chemistry and channel but nearly opposite in investor character — and, less obviously, in how much variety each one hides.

CR4 = share of industry revenue held by the four largest firms (a "concentration ratio"); HHI = Herfindahl-Hirschman Index, the standard single-number concentration gauge; DTC = direct-to-consumer; CDMO = contract development and manufacturing organization; ADR = American Depositary Receipt (a foreign share traded on a U.S. exchange). Figures from the child primers and federal sources.[1][2][3][4][11] One boundary note: the two children's pages do not agree on where toothpaste sits — the beauty child claims dentifrices within its 325620 scope, while the cleaning child's own six-digit table lists toothpaste under soap & detergent (325611). We follow the beauty child, which matches the federal 325620 definition, but the overlap is worth knowing when comparing category data.[3][4]

The three contrasts that matter most:

1. Similar size, opposite trajectories — and opposite internal variety. The two children are close in scale — roughly a 56/44 split of receipts and a 54/46 split of jobs — so neither dominates the group.[1][3][4] But they travel differently. Soap & cleaning is the more defensive and flatter of the two: laundry, dishes, and disinfecting track the number of households, and its swing comes from a capital-heavy surfactant tail exposed to cyclical farm, oil, and construction demand (soft in 2024, stronger in 2025).[3] Beauty is also recession-resilient but has a real growth engine — premiumization, where shoppers trade up and revenue rises faster than unit volume, amplified by a mid-2020s fragrance boom; Circana measured U.S. prestige beauty retail up 4% and mass-market beauty up 5% in 2025, with prestige fragrance up 5% and mass fragrance up 15%.[4][7] The children also differ in homogeneity: cleaning is three unlike businesses averaged together, beauty is one.

2. The public/private map is the sharpest difference. On the cleaning side there is no way to buy a focused, U.S.-listed cleaning company — public investors get exposure only as a slice of diversified consumer-staples giants (Procter & Gamble, Colgate-Palmolive, Church & Dwight, Clorox), with a single chemical pure-play at the surfactant end; everything focused is private.[3] And that lone pure-play is small: Stepan carries roughly $1.1 billion of market value on ~$2.2 billion of 2024 sales — the only direct listed claim on a $45.8 billion child.[3] On the beauty side, by contrast, the pure-plays are listed — Estée Lauder, Coty, e.l.f. Beauty, Inter Parfums, Oddity Tech, Olaplex — so a stock-picker can own the category directly.[4] Same group, two completely different playbooks.

3. Both are branded oligopolies on fragmented bases — but the fragments differ. Under the giants, cleaning's long tail is artisan and contract soap makers plus specialty co-packers; beauty's is thousands of indie and DTC brands that outsource production to contract manufacturers.[3][4] In both, private equity's favorite target is the same brand-agnostic contract-manufacturing layer — the "picks and shovels" that make product for whichever brand is winning this year. Note, though, that outsourcing is not universal even in beauty: Coty made approximately 81% of its fiscal-2025 products internally and bought approximately 19% from third parties.[10]

3. How big it is (the group rollup)

Federal ground-truth figures for the whole four-digit group (U.S. establishments only):

The Economic Census is the once-every-five-years full count of U.S. businesses; County Business Patterns (CBP) is the Census Bureau's annual establishment-and-employment series.

How the two children add up. The group ties out almost perfectly to its parts. Establishments (1,406 + 1,096 = 2,502) and employment (57,187 + 48,968 = 106,155) match to the exact number; annual payroll ($4.22B + $3.29B = $7.51B) matches; and receipts sum to ~$82.33B against the group's $82.38B — a rounding-level gap.[3][4] Only firm counts don't add cleanly (1,252 + 1,131 = 2,383 versus 2,370 at the group), because a company operating in both children — Procter & Gamble spans laundry and beauty, for example — is counted once at the rollup. That is a normal feature of how the Census aggregates, not an error.

One figure to hold loosely: headcount. The 106,155 above is internally consistent because both children are measured on the same CBP basis. A different federal survey reads higher: the Bureau of Labor Statistics' CES benchmark puts beauty alone (32562) at 58,200 jobs in March 2023, against CBP's 48,968 for the same industry — which is why the beauty child now reports its employment as a 49,000–58,000 range rather than a point estimate.[4][5] The two surveys use different coverage and definitions; we do not build a revised group total from the higher number, because mixing bases across children would manufacture a statistic. Read the group's employment — and the revenue-per-worker ratios derived from it — as the softest numbers on this page.

Concentration — and why the group looks less concentrated than either child. For the group as a whole:

Notice that the group's CR4 (38.0%) is lower than either child's (42.8% for cleaning, 46.5% for beauty).[1][3][4] That is not a rounding quirk — it is structural. The four biggest cleaning firms and the four biggest beauty firms are largely different companies: P&G and Unilever straddle both sides, but soap's other leaders (Church & Dwight, Clorox, Reckitt, S.C. Johnson) are not beauty's (Estée Lauder, L'Oréal, Coty). Pooling two industries with mostly distinct leaders spreads the top-4 share across more names, so the combined figure reads less concentrated than the arenas it contains.

The effect compounds on the cleaning side, which is itself an average of three unlike structures: a highly concentrated detergent tier (top four ~60%), a fragmented polish and sanitation tier (top four ~25%, HHI ~252), and a surfactant tier concentrated at the very top (top four ~63%, top twenty ~90%).[3] So the group's 38.0% is an average of an average — a statistic about a pooled statistical category, not about any arena in which firms actually compete. On the single-number gauge, the group's HHI is suppressed in the federal data, as is beauty's, so we do not report one here. The cleaning child now does carry one — 651.8, which reads "unconcentrated" under the federal antitrust yardstick (broadly, below ~1,000–1,500) — but a single child's HHI cannot be stretched to cover the group, and two HHIs cannot be added.[1][3][4]

Undercount and interpretation caveats:

1. These are U.S. factory-gate shipments, not U.S. consumption. The $82.4 billion measures what domestic plants ship; it excludes imported finished product and is not retail spending, which is far larger once imports, distributor margins, and store markups are added. How much larger is genuinely contested. For beauty alone, Mordor Intelligence puts the U.S. retail market at roughly $130 billion for 2025, while Circana's measured retail data report $36.0 billion of prestige beauty and $72.7 billion of mass-market beauty for the same year — differently scoped and differently measured series that we present as reported rather than reconciling or combining.[4][6][7] Either way the retail figure dwarfs the $36.5B this industry ships from domestic plants. Nor is any of this a single company's size: P&G's global Fabric & Home Care segment alone did roughly $29.6 billion worldwide in fiscal 2025 — more than half of everything the entire U.S. cleaning child ships — because most of it is made and sold abroad.[3][8]
2. The plant count understates how many businesses "make" these products. CBP counts only employer establishments. On the cleaning side, thousands of hobbyist and artisan soap makers with no paid employees fall outside the count, and surfactant made captively inside a detergent or petrochemical complex is booked to that plant's primary product rather than to surfactants.[3] On the beauty side, the fast-growing asset-light indie brands that outsource all manufacturing to contract makers usually aren't counted here as manufacturers at all (they show up, if anywhere, under wholesale or company management) — so the number of "beauty businesses" vastly exceeds 2,370 firms.[4] The census counts factories, not brands.
3. Foreign ownership is invisible here. A large share of U.S. output comes from U.S. subsidiaries of foreign multinationals (L'Oréal, Unilever, Shiseido, Beiersdorf, Reckitt, Henkel, Kao), so a domestic firm count understates how concentrated global brand ownership really is.[3][4] For scale: L'Oréal alone reported €11.7 billion of North America revenue in 2025 out of €44.05 billion globally — a sales measure, not a shipments measure, and so not directly comparable, but large against the $36.5 billion the whole beauty child ships from U.S. plants.[9]

4. The investable universe — where value concentrates across the children

There is no pure-play at the group level, and — the key point — value is reachable very differently in each child. Tickers and scale are reserved here and in Section 10.

Beauty (32562) — this is where the listed pure-plays are. A public investor who wants focused exposure to this whole group realistically gets it here:

• U.S.-listed pure-plays: The Estée Lauder Companies (EL), Coty (COTY), e.l.f. Beauty (ELF), Inter Parfums (IPAR), Oddity Tech (ODD), Olaplex (OLPX).[4]
• Diversified consumer names with beauty segments: Kenvue (KVUE), Edgewell Personal Care (EPC), Church & Dwight (CHD), Procter & Gamble (PG), Colgate-Palmolive (CL).[4]
• Foreign majors via ADRs: L'Oréal, Unilever, Shiseido, Beiersdorf, Kao.[4][9]
• Private layer: Chanel, Puig, direct-sales firms, Revlon (private since emerging from Chapter 11 reorganization), and the private-equity-owned contract-manufacturing tier (kdc/one, Voyant Beauty, Elevation Labs, Innovative Beauty Group).[4]

Cleaning (32561) — value sits inside diversified giants, with one small chemical exception. No focused consumer stock exists; instead:

• Diversified staples that straddle soap, detergent, and cleaning: Procter & Gamble (PG, the category leader, with more than 50% of U.S. retail laundry share across liquid, unit-dose, and powder), Colgate-Palmolive (CL), Church & Dwight (CHD, most laundry-concentrated), Clorox (CLX), Energizer (ENR, auto care), Ecolab/STERIS (ECL/STE, institutional hygiene).[3]
• The one surfactant pure-play: Stepan Company (NYSE: SCL) — ~$1.1B market value on ~$2.2B of 2024 sales, surfactants about three-fifths of the total, and a 58-year run of consecutive dividend increases. It is the only way to own the cleaning-chemistry end directly on a U.S. exchange; Dow (DOW) and Innospec (IOSP) give diluted exposure.[3]
• Foreign brand owners via ADRs: Unilever, Reckitt, Henkel, Kao.[3]
• Private layer: family firms (S.C. Johnson, ~$11.8B of revenue — larger, globally, than a quarter of everything this group ships domestically; Turtle Wax; Dr. Bronner's), PE roll-ups of cleaning brands (PurposeBuilt Brands, KIK), private surfactant specialists (Nouryon, Pilot Chemical, Colonial Chemical), and contract/private-label makers such as First Quality.[3]

Bottom line for allocators: public money buys diversified, defensive baskets across both children, plus focused beauty pure-plays and one small surfactant name. Anyone wanting a concentrated bet on cleaning manufacturing — or on the contract-manufacturing "picks and shovels" that serve both children — is looking at private companies.

5. How the money works

Both children make money the way branded consumer manufacturers do — units sold × price, minus the cost of goods and the marketing needed to move them — and in both the physical product is a small fraction of the price. The differences are of degree.

• Brand is the moat; the formula is cheap. In both children, buyers pay for trust, scent, and shelf presence far more than for ingredients. Beauty takes this furthest — prestige products routinely run 70–80% gross margins, and even a mass-market name like e.l.f. reported 70.7% in fiscal 2026, because formula and packaging are a small slice of retail price.[4][11] Cleaning's branded leaders earn healthy but lower margins, and its private-label/contract makers compete almost purely on cost; for disinfectants the brand doubles as a safety claim, which reinforces pricing power.[3]
• Marketing intensity is the shared engine — and the shared cost. Advertising plus "trade spend" (payments to retailers for shelf space) is among the largest line items in both. In beauty, ad spend often runs 15–25%+ of sales amid constant launches and social-media-driven trends — e.l.f.'s total selling, general and administrative expense reached 63% of sales in fiscal 2026, a reminder that these are brand-economics businesses wearing a manufacturer's classification code; in cleaning, the equivalent spend sustains brand pricing power.[3][4][11] The spend is what builds the moat — and a big chunk of every sales dollar reinvested just to hold share.
• Capital intensity clusters at one edge. Most of the group is asset-light blending and packaging. The exception is the surfactant chemistry inside 32561 — expensive, continuous-process plants that are most profitable when run full, so capacity utilization and the feedstock spread dominate their earnings. The scale is visible in the capex: Stepan's new Pasadena, Texas alkoxylation plant cost $220 million for 75,000 tonnes a year of capacity and started up in April 2025, while trouble at its Millsdale, Illinois complex dropped earnings directly in 2024.[3] This is the group's only genuinely capital-heavy corner, and its only real cyclicality.
• Two factory models under the brands — but the split is not uniform. Both children have a contract-manufacturing layer (co-packers in cleaning, CDMOs in beauty) that runs a classic keep-the-plant-full, thin-margin-on-volume model — brand-agnostic cash flow that private equity prizes.[3][4] It would be wrong, though, to read every brand owner as asset-light: Coty manufactured approximately 81% of its fiscal-2025 products in its own plants.[10] Institutional-hygiene players on the cleaning side add a stickier "razor-and-blade" twist (place dispensers on-site, sell concentrated refills on contract), and surfactant makers run a comparable "toll" model, converting a customer's feedstock for a fee without taking commodity risk.[3]
• The input-cost spread is the quarterly swing factor. Shared raw materials — surfactants and their feedstocks (petrochemical and palm/coconut oleochemicals), fragrances, and packaging resin — move with commodity and oil markets. Because volumes barely grow, near-term earnings across the group turn on the gap between selling prices and input costs, which producers pass through with a lag.[3][4]
• One cost layer the cleaning side doesn't carry: licensing. Much of prestige fragrance is made under brand licences, and the royalties are real money — Coty disclosed $853 million of future contractual royalty payments at June 2025. There is no cleaning-side analogue.[10]

Net: a defensive, cash-generative group where winners compound through brand pricing and marketing — with beauty offering higher margins and more growth, and cleaning offering more defensiveness plus one capital-intensive, more cyclical chemical tail.

6. What drives demand

• Households and population — the shared floor. Both children ultimately track the number of people washing, grooming, and cleaning. That grows slowly and steadily, which is why the whole group is defensive but not fast-growing.[3][4]
• Premiumization and trade-up/trade-down cycles. The biggest organic lever, strongest in beauty: buyers trading up to prestige skincare, premium fragrance, pods, concentrates, and eco formats lift revenue faster than unit volume. Circana measured U.S. prestige beauty retail sales up 4% and mass beauty up 5% in 2025.[7] In downturns the reverse happens — shoppers shift to private label and value brands — and this mix shift moves profitability more than total volume does.[3][4]
• The fragrance boom — beauty's sharpest current driver. Prestige fragrance grew 5% and mass fragrance 15% in 2025, the clearest evidence that the mid-2020s scent cycle has not yet rolled over.[4][7]
• Demographics and "skinification." An aging population fuels anti-aging skincare; Gen Z fuels color cosmetics and fragrance; men's grooming and treatment-oriented hair and scalp care are growth pockets — beauty-specific drivers with no cleaning analog.[4]
• Hygiene awareness, health scares, and away-from-home activity. Hand soap, sanitizer, and disinfectant volumes spike around health events (as in 2020–21) then normalize; the pandemic left a higher structural cleaning baseline but no repeat spike. Institutional demand (restaurants, hotels, hospitals, food processing) adds a cyclical layer tied to travel, dining, and infection-control standards — cleaning-specific drivers.[3]
• Social media, influencers, and DTC. Trends and launches increasingly originate online, compressing product cycles — most visibly in beauty, where a viral moment can build or break a brand.[4]
• Sustainability as a value lever, not just a cost. Concentrates, refills, plastic reduction, plant-based formulas and — at the chemical end — bio-based and fermentation-made surfactants are pulling the cleaning side toward higher-margin specialty chemistry, the nearest thing it has to beauty's premiumization.[3]
• Cyclical end markets — unique to surfactants. A slice of cleaning-side surfactant demand feeds agriculture, oilfield, and construction, adding cyclical swing beyond the steady consumer core; those markets were soft in 2024 and stronger in 2025.[3]

7. Regulation

Because the group spans personal-care products, health-claim products, and industrial chemicals, it draws on overlapping regulators — and the direction of travel is the same across both children: tighter ingredient scrutiny, more disclosure, and sustainability/packaging pressure, all of which favor scale because large firms absorb compliance cost more easily than small ones.

• FDA (Food and Drug Administration) sits over both — but asymmetrically. On the beauty side, the landmark change is the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) — the biggest expansion of FDA authority over cosmetics since 1938, with core requirements (facility registration, product-and-ingredient listing, Good Manufacturing Practices, safety substantiation, adverse-event reporting) enforced from July 1, 2024; a partial small-business exemption means the net effect favors scale.[4][12] Even post-MoCRA, though, the FDA generally does not approve cosmetics or their ingredients before sale (regulated color additives are the exception), and "cosmeceutical" is not a legal category.[4] On the cleaning side, antibacterial soaps and hand sanitizers are instead regulated as over-the-counter drugs — the FDA's 2016 rule (effective September 2017) barred 19 antibacterial ingredients including triclosan, forcing broad reformulation.[3]
• The clearest cross-child contrast: pre-market clearance. A new lipstick can ship without FDA sign-off; a disinfectant that claims to kill a pathogen cannot ship at all until it is registered under FIFRA (the Federal Insecticide, Fungicide, and Rodenticide Act) with efficacy data behind the claim. Disinfectants and sanitizers are legally antimicrobial pesticides. That registration cost is one of the highest genuine entry barriers anywhere in the group, and it sits entirely on the cleaning side.[3][4]
• 1,4-dioxane — the cross-cutting chemistry issue. This trace contaminant forms during ethoxylation (a common surfactant reaction), so it links both children. In November 2024 the EPA finalized an "unreasonable risk to human health" determination that specifically included byproduct exposure from ethoxylation among the evaluated conditions of use, and began risk-management rulemaking. New York caps household cleaning and personal-care products at ≤1 part per million, with all waivers expiring December 30, 2025; California's Safer Consumer Products program moved in 2026 to list high-dioxane dish detergents and shampoos as "Priority Products."[3]
• EPA (Environmental Protection Agency) and chemical rules — mostly cleaning-side. The Toxic Substances Control Act (TSCA) governs ingredients; the EPA's voluntary Safer Choice label is a marketing edge for greener formulas. State phosphate bans (which pushed dishwasher detergents phosphate-free nationwide by 2010) and VOC (volatile organic compound) limits further constrain formulas and aerosols.[3]
• Color additives, Prop 65, and state ingredient bans — beauty-side. FDA color-additive approval, federal labeling rules, California's Proposition 65, a growing wave of state ingredient bans, and the stricter EU regime for exporters all raise the compliance bar; "organic" claims on cosmetics run through USDA's National Organic Program, not the FDA.[4]
• PFAS, product safety, and disclosure — shared. "Forever chemicals" scrutiny, ingredient-transparency ("right to know") laws, child-resistant packaging (tightened after laundry-pod ingestion incidents), and workplace/transport chemical-handling rules cut across both children.[3][4]

8. Consolidation

The whole group is a branded oligopoly resting on a fragmented base, and deal-making runs constantly through both children — in complementary forms.

• Beauty (32562): strategics buy indie brands; PE buys the factories. Big brand owners routinely acquire fast-growing indie labels to refresh their portfolios, while private equity has targeted the contract-manufacturing (CDMO) layer for its brand-agnostic cash flow — kdc/one, Voyant Beauty, Elevation Labs, and Innovative Beauty Group are all sponsor-owned. Incumbents periodically review whether to shed beauty divisions, and the category's distress route runs the same way: Revlon emerged from Chapter 11 as a private company rather than returning to the public market.[4]
• Cleaning (32561): portfolio pruning, PE roll-ups, and cross-border chemistry. The majors have been shedding thin-margin volume — Henkel closed the sale of its North American private-label detergent business (~€500M) to First Quality in 2025, and Reckitt completed the sale of a majority interest in Essential Home (Air Wick, Cillit Bang, Resolve, Easy-Off) to Advent International at the end of 2025, retaining a 30% stake. PE has rolled up specialty cleaning brands (PurposeBuilt Brands, now held by Rock Mountain Capital and The Olayan Group), institutional cleaning has consolidated (Solenis' $4.6 billion purchase of Diversey in 2023), and the surfactant end has seen cross-border deals — Thailand's Indorama buying Huntsman's surfactants business for ~$2B in 2020, South Korea's Samyang buying Verdant Specialty Solutions for ~$250M in 2023.[3]
• The shared thread: in both children, private equity's preferred entry point is the same contract-manufacturing tier — the picks-and-shovels that make product for whoever's brand is winning. The strategics' preferred exit is the mirror image: sell the low-margin volume, keep the brand.

Barriers to entry are high at the branded and chemical tiers — brand equity, national advertising, retailer shelf access, FIFRA/EPA registration, and (for surfactants) capital-intensive plants — but low at the commodity/private-label/indie end, where a contract manufacturer plus a retail or online relationship is enough to compete. That split — a concentrated top on a fragmented bottom — is exactly why the group's concentration reads as only moderate.

9. Risks

• Input costs and tariffs (shared, and currently biting hardest in beauty). Surfactants, oleochemicals/palm oil, fragrance oils, and packaging resin swing with commodity and oil markets; duties on imported ingredients and packaging rose sharply in 2025. The exposure is concrete: e.l.f., which sources and manufactures the majority of its products through third parties in China, attributed its fiscal-2026 gross-margin decline primarily to tariffs.[4][11] When costs jump faster than prices can follow, the margin spread compresses across both children.[3]
• Trend risk vs. trade-down risk (the two children's characteristic exposures). Beauty is fashion- and social-media-driven — brands fatigue, and heavy marketing is needed just to hold share, with private label, lower-priced "dupes," and imported K-beauty competing for the same shelf.[4] Cleaning's mirror risk is private-label trade-down: in downturns shoppers shift to cheaper store brands, pressuring branded volume and mix.[3]
• Retailer and channel concentration (shared). A few enormous retailers control shelf access and terms, and they can destock or reallocate space without any change in end-consumer demand. In fiscal 2026 Target, Walmart, Amazon, and Sephora accounted for 18%, 13%, 11%, and 10% of e.l.f.'s sales respectively — a fair illustration of the dependence on both sides of the group.[11] Prestige beauty adds reliance on China and travel-retail demand.[4]
• Supply-chain concentration (beauty-side). Asset-light brands trade plant capital for supplier dependence — specialized pumps, applicators, and single-source ingredients create lead-time and capacity-allocation risk that a vertically integrated manufacturer does not carry.[4]
• Regulatory and litigation exposure (shared). MoCRA compliance, ingredient bans (triclosan-style), FIFRA registration cost, 1,4-dioxane and PFAS scrutiny, talc/asbestos suits, VOC limits, and sustainability/packaging mandates all raise cost and legal risk — and disproportionately burden small players.[3][4]
• Demand normalization and cyclicality (cleaning-side). The pandemic hygiene surge reversed into a multi-year destocking hangover — cleaning-wipe sales fell more than 25% in the year to September 2022 — and the surfactant tail's farm/oil/construction exposure, sitting on heavily fixed plant costs, amplifies downturns.[3]
• ESG, reputational, and operational shocks (mostly cleaning-side). Palm-oil deforestation, single-use plastic, aerosol and benzene recalls, and "greenwashing" claims draw activist and regulatory attention; discrete operational events bite too, as Clorox's 2023 cyberattack showed.[3]
• Private-market cyclicality (beauty-side). Funding and exit windows for the DTC/indie layer can freeze, stranding capital in the private tier where much of beauty's growth lives.[4]
• Structurally modest growth (shared). These are mature categories; volumes roughly track population, so the group is defensive but offers limited organic top-line growth — and on the cleaning side, thin public float (no consumer pure-play, one small chemical name) concentrates equity risk.

10. How to invest and the outlook

The group's defining investor feature is that its two children call for two different playbooks.

Public-market routes.

• Focused exposure lives in beauty (32562): the pure-plays — Estée Lauder (EL), Coty (COTY), e.l.f. Beauty (ELF), Inter Parfums (IPAR), Oddity Tech (ODD), Olaplex (OLPX) — let a stock-picker own the category directly; this is a stock-pickers' sector with dispersed outcomes.[4]
• Cleaning (32561) is a diversified-staples trade: Procter & Gamble (PG), Church & Dwight (CHD), Colgate-Palmolive (CL), Clorox (CLX), Energizer (ENR), and — for institutional hygiene — Ecolab (ECL)/STERIS (STE), plus the lone surfactant pure-play Stepan (SCL), a small-cap and long-running dividend raiser that carries single-plant and feedstock risk in exchange for being the cleanest listed proxy for U.S. surfactant volumes and margins. Dow (DOW) and Innospec (IOSP) give diluted chemical exposure.[3]
• Diversified names span both children: PG, CHD, and CL each carry meaningful soap and beauty exposure; Kenvue (KVUE) and Edgewell (EPC) tilt beauty/personal-care.[3][4]
• Foreign majors via ADRs: L'Oréal, Unilever, Shiseido, Beiersdorf, Reckitt, Henkel, Kao.[3][4][9]
• Index route: there is no dedicated U.S.-listed soap/cleaning or beauty ETF, so most exposure is built through individual names or broad consumer-staples/discretionary funds (e.g., XLP, VDC), in which these companies appear as slices — and the surfactant end shows up only as a sliver of materials-sector funds.[3][4]

The cleaning names are generally dividend-oriented and defensive (owned for stability and yield); the beauty names skew growth-tilted and more dispersed (owned for premiumization upside, at higher trend risk).

Private-market routes. The focused, higher-purity opportunities are private and differ by child: on the cleaning side, contract/private-label makers, artisan and regional soap brands, family firms (S.C. Johnson, Turtle Wax), PE roll-ups, and specialty/biosurfactant producers; on the beauty side, CDMO contract manufacturers, indie-brand roll-ups, and early-stage DTC startups.[3][4] The contract-manufacturing tier — the brand-agnostic "picks and shovels" common to both children — is the single most PE-active corner of the group. The diligence question that separates good deals from bad ones is which profit pool is actually being bought: brand equity and customer acquisition, licensed intellectual property, formulation and regulatory capability, or plain physical filling capacity.[4] These give purer exposure to the manufacturing itself, at the cost of illiquidity and single-brand risk. PE = private equity.

Near-term drivers to watch (forward-looking). Expect low-single-digit volume growth in line with households across the group, with premiumization (strongest in beauty) doing most of the work of lifting revenue ahead of volume. The bigger swing factors: the margin spread as input-cost and, now, tariff pressure eases or persists — currently the most visible drag on the beauty side; private-label share on the cleaning side, which tends to climb while budgets are tight; the durability of the fragrance and prestige-beauty boom, still growing through 2025; volume recovery in the pandemic-distorted cleaning category and in cyclical surfactant end markets, which firmed in 2025 after a soft 2024; and continued M&A — strategics buying indie brands, majors shedding thin-margin cleaning volume, and PE consolidating contract manufacturing across both children. The reasonable base case is a steady, cash-generative, competitively intense group — attractive for defense and income on the cleaning side, and for premiumization-driven growth (at higher trend, tariff, and private-market risk) on the beauty side.

---

Sources

1. U.S. Census Bureau, "2022 Economic Census — Concentration by Largest Firms, NAICS 3256" (group receipts $82.38B; firms 2,370; CR4 38.0%, CR8 46.1%, CR20 57.2%, CR50 70.3%; HHI suppressed), 2022. https://www.census.gov/programs-surveys/economic-census.html
2. U.S. Census Bureau, "County Business Patterns 2023 — NAICS 3256" (establishments 2,502; employment 106,155; annual payroll $7.51B; first-quarter payroll $1.94B), 2023. https://www.census.gov/programs-surveys/cbp.html
3. Histometrics child primer, "Soap and Cleaning Compound Manufacturing (NAICS 32561)" — synthesizing the 2022 Economic Census and 2023 CBP; receipts $45.83B, firms 1,252, establishments 1,406, employment 57,187, payroll $4.22B, CR4 42.8%/CR8 51.5%/CR20 63.7%/CR50 77.7%, HHI 651.8; six-digit split 325611 ~$27.2B (CR4 59.6%), 325612 ~$8.4B (CR4 24.7%, HHI 251.7), 325613 ~$10.2B (CR4 62.5%, top-20 90%); P&G Fabric & Home Care (~$29.6B FY25) and >50% U.S. laundry share; Stepan (SCL) scale, Pasadena start-up April 2025, Millsdale 2024; S.C. Johnson (~$11.8B); Henkel/First Quality (~€500M, 2025); Reckitt/Advent Essential Home (30% retained, 2025); Solenis–Diversey ($4.6B, 2023); Indorama–Huntsman (~$2B, 2020); Samyang–Verdant (~$250M, 2023); FDA 2016 antibacterial rule; FIFRA; EPA 1,4-dioxane (Nov 2024), New York waiver expiry Dec 30 2025 and California 2026 Priority Products; post-pandemic wipe-sales decline >25%.
4. Histometrics child primer, "Toilet Preparation Manufacturing (NAICS 32562)" — 2022 Economic Census and 2023 CBP; receipts $36.5B, firms 1,131, establishments 1,096, employment 48,968 (CBP) against a 49,000–58,000 range, payroll $3.29B, first-quarter payroll $846.2M, CR4 46.5%/CR8 53.9%/CR20 66.3%/CR50 78.7% (HHI suppressed); single six-digit child 325620; Estée Lauder (EL), Coty (COTY), e.l.f. (ELF), Inter Parfums (IPAR), Oddity (ODD), Olaplex (OLPX), Kenvue (KVUE), Edgewell (EPC); L'Oréal/Shiseido/Beiersdorf/Kao ADRs; CDMO tier (kdc/one, Voyant Beauty, Elevation Labs, Innovative Beauty Group); Revlon private post-Chapter 11; MoCRA and FDA pre-market limits; premiumization and the fragrance boom.
5. U.S. Bureau of Labor Statistics, "CES Benchmark Article, Table 1 — NAICS 325620 employment" (58,200 jobs, March 2023), 2023. https://www.bls.gov/ces/publications/benchmark/cesbmart23-tables.htm
6. Mordor Intelligence, "United States Beauty and Personal Care Products Market" (~$130.25B retail, 2025), 2025. https://www.mordorintelligence.com/industry-reports/united-states-beauty-and-personal-care-products-market
7. Circana, "U.S. Prestige and Mass Beauty Retail Deliver a Positive Performance in 2025" (prestige $36.0B, +4%; mass $72.7B, +5%; prestige fragrance +5%, mass fragrance +15%), 2025. https://www.circana.com/post/us-prestige-and-mass-beauty-retail-deliver-a-positive-performance-in-2025-circana-reports
8. Procter & Gamble, "Form 10-K, Fiscal Year 2025 — Fabric & Home Care segment results" (~$29.6B worldwide), 2025. https://www.sec.gov/Archives/edgar/data/80424/000008042425000076/pg-20250630.htm
9. L'Oréal, "2025 Annual Results" (global sales €44.05B; North America €11.72B), 2025. https://www.loreal-finance.com/eng/press-release/2025-annual-results
10. Coty Inc., "Fiscal 2025 Form 10-K" (approximately 81% internal manufacturing / 19% third-party; $853M of future contractual royalty payments at June 2025), 2025. https://www.sec.gov/Archives/edgar/data/1024305/000102430525000030/coty-20250630.htm
11. e.l.f. Beauty, Inc., "Fiscal 2026 Form 10-K" (70.7% gross margin; SG&A 63% of sales; tariff-driven margin decline; Target 18%, Walmart 13%, Amazon 11%, Sephora 10% of sales), 2026. https://www.sec.gov/Archives/edgar/data/1600033/000160003326000020/elf-20260331.htm
12. U.S. Food and Drug Administration, "Modernization of Cosmetics Regulation Act of 2022 (MoCRA)" (core requirements enforced July 1, 2024), 2024. https://www.fda.gov/cosmetics/cosmetics-laws-regulations/modernization-cosmetics-regulation-act-2022-mocra